ATRICURE, INC. (NASDAQ:ATRC) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.
On February 28, 2017, AtriCure, Inc.issued a press release
regarding its financial results for the fourthquarter and full
year ended December 31, 2016. The Company will hold a conference
call on February 28, 2017 at 4:30 p.m. Eastern Time to discuss
the financial results. A copy of the press release is furnished
as Exhibit 99.1 to this Form 8-K and is incorporated herein by
reference.
The information in this Item2.02 of Form 8-K and in the press
release attached as Exhibit 99.1 is being furnished and shall not
be deemed “filed” for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that Section. The information in
Item2.02 of this Form 8-K and Exhibit 99.1 shall not be
incorporated by reference in any filing or other document under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in any such
filing or document.
Item 9.01Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
No. |
Description |
|
99.1 |
Press Release dated February 28, 2017relating tofinancial |
About ATRICURE, INC. (NASDAQ:ATRC)
AtriCure, Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. Its Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. ATRICURE, INC. (NASDAQ:ATRC) Recent Trading Information
ATRICURE, INC. (NASDAQ:ATRC) closed its last trading session up +0.21 at 19.16 with 456,138 shares trading hands.
